Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532277 | 1.00 | GRM2 (0.41) | GRM2 | |
| SCHEMBL14436443 | 0.88 | CALML3 (0.49) | — | |
| SCHEMBL5531661 | 0.87 | GRM2 (0.39) | GRM2 | |
| SCHEMBL5531671 | 0.87 | GRM2 (0.39) | GRM2 | |
| SCHEMBL411075 | 0.81 | GRM2 (0.41) | GRM2 | |
| SCHEMBL5532796 | 0.81 | GRM2 (0.36) | GRM2 | |
| SCHEMBL5532801 | 0.81 | GRM2 (0.36) | GRM2 | |
| SCHEMBL411619 | 0.80 | GRM2 (0.40) | GRM2 | |
| SCHEMBL412766 | 0.80 | F10 (0.40) | GRM2 | |
| SCHEMBL7076968 | 0.78 | GRM2 (0.51) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | claimed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | claimed |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | GRM2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.